RECEIVED CENTRAL FAX CENTER

JUL 27 2005

					U.S. Patent	and Trademade	Officer	PTO/SB/21 (09-04) through 07/31/2006. CMB 0651-0031 J.S. DEPARTMENT OF COMMERCE	
Under the Pan	enwork Re	eduction Act of 1995	no person	are required to rescond to Application Number	a collection	of information	untess it.	displays a valid OMB control number.	
					24,406	,			
TRANSMITTAL			Filing Date		November 28, 2000				
FORM			First Named Inventor		Francisco, Joseph				
			Art Unit	1642					
(to be used for all correspondence after initial filing)			Examiner Name	Yu, t	Yu, Misook				
Total Number of Pages in This Submission 50				Attorney Docket Num	ber ₉₆₃₂	-006-999			
			ENC	LOSURES (Chec	k all that a	apply)			
Fee Trans	smittal Fo	erm	l -	Drawing(s)				Ulowance Communication to TC	
L_J F€	e Attach	ed		Licensing-related Papers	\$			eals and interferences	
Amendme	ent/Penki	,		Petition				I Communication to TC I Notice, Brief, Reply Brief)	
<u> </u>				Petition to Convert to a			Propri	etary Information	
▎ ├┤ [▗] ॉ	ter Final			Provisional Application Power of Attorney, Revo			•	<u>-</u>	
	fidavits/d	leclaration(s)	片 '	Change of Corresponde	nce Addre		Status Letter Other Enclosure(s) (please Identify		
Extension	of Time	Request	┧╚┛╵	Terminal Disdaimer			below) :	
Express A	Abandoni	ment Request		Request for Refund				upplementary European Search iges); PTO/SB/08A (1 page); DE	
		sure Statement		SO Number of CO(s)		196	40 733 .	A1 (8 pages); and EP 0 678 523	
L▼1 Intomistic	m Disclo	Přilá Sidiemstr		AT (36 pages)		S)			
	D	Bulacutto.	I Danie	Landscape Table	on CD				
Certified C		rnonty	Rema	IKB					
Reply to h	Missing P	arts/							
Ll Incomplet		ation issing Parts							
		FR 1.52 or 1.53							
			ļ						
		SIGNA	TURE	F APPLICANT, A	TTORNE	Y, OR AG	ENT		
Firm Name	Seattle	Genetics, Inc.							
Signature	(1)	1) (-1-		•				
Printed name	Printed name Vita Conforti		7			-			
Date July 27, 2005				Reg. I	Vo. 36,639)			
CERTIFICATE OF TRANSMISSION/MAILING									
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.									
Signature		Rolaus	4/ 1	XXIIII VY					
Typed or printed name Roxanne J. Holmes			1 1 1)			Date	July 27, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUL 27 2005

I hereby certify that this correspondence is being facsimite transmitted to the Patent and Trademark Office (Fax No. 571-273-
8300 on July 27, 2005 by Roxanne J. Holmes.
Date of Deposit Name
Robanne X Volum

PATENT Our Case No.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application of: Francisco et al.	
Serial No.: 09/724,406	Group Art Unit: 1642
Filed: November 28, 2000	Examiner: Yu, Misook
For: RECOMBINANT ANTI-CD3 THEREOF	O ANTIBODIES AND USES

FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the obligation recited in 37 C.F.R. § 1.56 and in conformance with 37 C.F.R. §§ 1.97-1.98, Applicants request consideration of this Information Disclosure Statement in prosecution of this application. Pursuant to 37 C.F.R. § 1.97(e)(1), no fee or certification is required because each item of the information disclosed in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing of the present statement.

RECEIVED CENTRAL FAX CENTER

JUL 27 2005

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Page 1975 Page 1975

Substitute for form 1449/PTO	Co	Complete if Known			
Substitute to 15th 1777	Application Number	09/724,406			
INFORMATION DISCLOS	Filing Date	November 28, 2000			
INFORMATION DISCLOS	I I IIST MAILIAG HIVAGITON	Francisco, Joseph			
STATEMENT BY APPLIC	ANT Art Unit	1642			
(Use as many sheets as necessary)	Examiner Name	Yu, Misook			
heet 1 of 1	Attorney Docket Number	9632-006-999			

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (f known)}			Figures Appear
		^{US-} 5,677,430	10-14-1997	Goodwin, et al.	
		US-			
		U\$-			
		US-			
		US-			
		US-			
-		Ū\$-			
	 	US-			
		US-			
	i	US-			
	 	US-			
		บร			
		บร-			
		US-			
		U\$-			
	 	US-			
		US-			
	 	US-			
	 	US-			_

	FOREIGN PATENT DOCUMENTS						
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentoe or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
<u> </u>		Country Code ³ Number ⁴ Kind Code ⁵ (if Known)	MM-DD-YYYY		Or Relevant Figures Appear	T°	
		DE 196 40 733 A1	04-09-1998	Abken, H.			
		EP 0 678 523 A	10-25-1995	Judicial Foundation of			
				Chemo-Sero Therapeutic			
				Research Institute			

Examiner	Date	
Signature	Considered	1

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Traisaction is anached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Avandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.